BiotechTube

Maralixibat

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholestasis of Pregnancy

Conditions

Intrahepatic Cholestasis of Pregnancy

Trial Timeline

Apr 1, 2026 → Mar 31, 2028

NCT ID
NCT07389031

About Maralixibat

Maralixibat is a phase 2 stage product being developed by Mirum Pharmaceuticals for Intrahepatic Cholestasis of Pregnancy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07389031. Target conditions include Intrahepatic Cholestasis of Pregnancy.

What happened to similar drugs?

0 of 4 similar drugs in Intrahepatic Cholestasis of Pregnancy were approved

Approved (0) Terminated (1) Active (3)
🔄A4250 (odevixibat)IpsenPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
❌Maralixibat + PlaceboMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT04530994Pre-clinicalCompleted
NCT07389031Phase 2Recruiting
NCT06553768Phase 3Recruiting
NCT04729751Phase 2Completed
NCT04524390Phase 2Completed
NCT04168385Phase 2Completed
NCT04185363Phase 3Completed
NCT03905330Phase 3Completed

Competing Products

20 competing products in Intrahepatic Cholestasis of Pregnancy

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
31
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
42
ApatinibJiangsu Hengrui MedicinePhase 2
35
FamitinibJiangsu Hengrui MedicinePhase 2
27
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
31
Durvalumab + SNDX-6352AstraZenecaPhase 2
35
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Pemigatinib + DurvalumabAstraZenecaPhase 2
42
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
42
PemigatinibIncytePhase 2
24
A4250 (odevixibat)IpsenPhase 3
37
OdevixibatIpsenPre-clinical
23
CGT4859Cogent BiosciencesPhase 1/2
36
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
32
MaralixibatMirum PharmaceuticalsPhase 3
37
MaralixibatMirum PharmaceuticalsPhase 2
32
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
24
MaralixibatMirum PharmaceuticalsPhase 3
37
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
29
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
23